持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2017/09/15 | 日証協 | 53,589株 | -36.9% | 22,343株 | -26.92% | 63,236株 | -33.43% | 14,880株 | -0.13% |
2017/09/08 | 日証協 | 84,922株 | -9% | 30,573株 | -36.62% | 94,989株 | -2.25% | 14,900株 | -22.52% |
2017/09/01 | 日証協 | 93,319株 | -4.1% | 48,237株 | +16.55% | 97,174株 | -0.72% | 19,232株 | +254.64% |
2017/08/25 | 日証協 | 97,312株 | -7.31% | 41,386株 | -39.79% | 97,874株 | -7.21% | 5,423株 | -81.86% |
2017/08/18 | 日証協 | 104,984株 | -4.05% | 68,735株 | +168.74% | 105,474株 | -4.27% | 29,901株 | +130.01% |
2017/08/10 | 日証協 | 109,419株 | +0.97% | 25,577株 | -66.11% | 110,173株 | +7.98% | 13,000株 | -57.77% |
2017/08/04 | 日証協 | 108,373株 | -31.59% | 75,477株 | -18.13% | 102,028株 | -19.11% | 30,785株 | +105.23% |
2017/07/28 | 日証協 | 158,409株 | +22.28% | 92,192株 | +15.02% | 126,128株 | +6.41% | 15,000株 | +66.67% |
2017/07/21 | 日証協 | 129,550株 | -1.61% | 80,153株 | +15.11% | 118,528株 | -0.17% | 9,000株 | -12.02% |
2017/07/14 | 日証協 | 131,673株 | -4.49% | 69,630株 | +20.6% | 118,728株 | -3.85% | 10,230株 | -50.35% |
2017/07/07 | 日証協 | 137,861株 | +9.94% | 57,734株 | -26.6% | 123,482株 | -23.52% | 20,604株 | -1.35% |
2017/06/30 | 日証協 | 125,401株 | +3.2% | 78,652株 | +14.73% | 161,461株 | +1.67% | 20,885株 | +75.93% |
2017/06/23 | 日証協 | 121,516株 | -16.71% | 68,554株 | -13.39% | 158,806株 | +4.09% | 11,871株 | -42.93% |
2017/06/16 | 日証協 | 145,899株 | +7.58% | 79,155株 | +22.18% | 152,566株 | -4.69% | 20,800株 | +16.44% |
2017/06/09 | 日証協 | 135,613株 | -7.27% | 64,788株 | -15.26% | 160,066株 | -6.99% | 17,864株 | -68.33% |
2017/06/02 | 日証協 | 146,238株 | +4.76% | 76,456株 | -20.23% | 172,104株 | +21.64% | 56,401株 | +11.76% |
2017/05/26 | 日証協 | 139,594株 | -4.78% | 95,846株 | -12.26% | 141,488株 | +13.64% | 50,465株 | +99.58% |
2017/05/19 | 日証協 | 146,594株 | +14.59% | 109,242株 | +32.77% | 124,503株 | -3.41% | 25,286株 | -16.54% |
2017/05/12 | 日証協 | 127,924株 | +2.49% | 82,277株 | +69.1% | 128,902株 | +0.16% | 30,298株 | +154.61% |
※株式分割は考慮していませんのでご注意ください。
Page Top